Literature DB >> 11101357

New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.

P Camps1, J Morral, D Muñoz-Torrero, A Badia, J E Baños, N M Vivas, X Barril, M Orozco, F J Luque.   

Abstract

Several new 12-amino-6,7,10,11-tetrahydro-7, 11-methanocycloocta[b]quinoline derivatives (tacrine-huperzine A hybrids, huprines) have been synthesized and tested as acetylcholinesterase (AChE) inhibitors. All of the new compounds contain either a methyl or ethyl group at position 9 and one or two (chloro, fluoro, or methyl) substituents at positions 1, 2, or 3. Among the monosubstituted derivatives, the more active are those substituted at position 3, their activity following the order 3-chloro > 3-fluoro > 3-methyl > 3-hydrogen. For the 1,3-difluoro and 1,3-dimethyl derivatives, the effect of the substituents is roughly additive. No significant differences were observed for the inhibitory activity of 9-methyl vs 9-ethyl derivatives mono- or disubstituted at positions 1 and/or 3. The levorotatory enantiomers of these hybrid compounds are much more active (eutomers) than the dextrorotatory forms (distomers) as AChE inhibitors. Compounds rac-20, (-)-20, rac-26, (-)-26, rac-30, (-)-30, and rac-31 showed human AChE inhibitory activities up to 28.5-fold higher than for the corresponding bovine enzyme. Also, rac-19, (-)-20, (-)-30, and rac-31 were very selective for human AChE vs butyrylcholinesterase (BChE), the AChE inhibitory activities being 438-871-fold higher than for BChE. Several hybrid compounds, specially (-)-20 and (-)-30, exhibited tight-binding character, showing higher activity after incubation of the enzyme with the inhibitor than without incubation, though the reversible nature of the enzyme-inhibitor interaction was demonstrated by dialysis. The results of the ex vivo experiments also supported the tight-binding character of compounds (-)-20 and (-)-30 and showed their ability to cross the blood-brain barrier. Molecular modeling simulations of the AChE-inhibitor complex provided a basis to explain the differences in inhibitory activity of these compounds.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101357     DOI: 10.1021/jm000980y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Huprines as a new family of dual acting trypanocidal-antiplasmodial agents.

Authors:  Julien Defaux; Marta Sala; Xavier Formosa; Carles Galdeano; Martin C Taylor; Waleed A A Alobaid; John M Kelly; Colin W Wright; Pelayo Camps; Diego Muñoz-Torrero
Journal:  Bioorg Med Chem       Date:  2011-01-21       Impact factor: 3.641

2.  The investigation of structure-activity relationships of tacrine analogues: electronic-topological method.

Authors:  Murat Saracoglu; Fatma Kandemirli
Journal:  Open Med Chem J       Date:  2008-08-06

3.  Binding free energy calculations to rationalize the interactions of huprines with acetylcholinesterase.

Authors:  Érica C M Nascimento; Mónica Oliva; Juan Andrés
Journal:  J Comput Aided Mol Des       Date:  2018-03-26       Impact factor: 3.686

Review 4.  Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy.

Authors:  Ashwani Arya; Rubal Chahal; Rekha Rao; Md Habibur Rahman; Deepak Kaushik; Muhammad Furqan Akhtar; Ammara Saleem; Shaden M A Khalifa; Hesham R El-Seedi; Mohamed Kamel; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Vineet Mittal
Journal:  Biomolecules       Date:  2021-02-25

5.  Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.

Authors:  Suresh K Bowroju; Narsimha R Penthala; Naga Rajiv Lakkaniga; Meenakshisundaram Balasubramaniam; Srinivas Ayyadevara; Robert J Shmookler Reis; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2021-07-14       Impact factor: 3.461

6.  Natural products as promising drug candidates for the treatment of Alzheimer's disease: molecular mechanism aspect.

Authors:  Niloufar Ansari; Fariba Khodagholi
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

7.  Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases.

Authors:  Joan Torrent; Alba Vilchez-Acosta; Diego Muñoz-Torrero; Marie Trovaslet; Florian Nachon; Arnaud Chatonnet; Katarina Grznarova; Isabelle Acquatella-Tran Van Ba; Ronan Le Goffic; Laetitia Herzog; Vincent Béringue; Human Rezaei
Journal:  Acta Neuropathol Commun       Date:  2015-04-03       Impact factor: 7.801

8.  Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease.

Authors:  Tao Su; Tianhua Zhang; Shishun Xie; Jun Yan; Yinuo Wu; Xingshu Li; Ling Huang; Hai-Bin Luo
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

9.  Undifferentiated and differentiated PC12 cells protected by huprines against injury induced by hydrogen peroxide.

Authors:  Marta Pera; Pelayo Camps; Diego Muñoz-Torrero; Belen Perez; Albert Badia; M Victoria Clos Guillen
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.

Authors:  Irene Sola; Albert Artigas; Martin C Taylor; F Javier Pérez-Areales; Elisabet Viayna; M Victòria Clos; Belén Pérez; Colin W Wright; John M Kelly; Diego Muñoz-Torrero
Journal:  Bioorg Med Chem       Date:  2016-08-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.